Influence of bradykinin on glucose 1,6-bisphosphate and cyclic GMP levels and on the activities of glucose 1,6-bisphosphatase, phosphofructokinase and phosphoglucomutase in muscle.
The intracellular concentration of glucose-1,6-bisphosphate (Glc-1,6-P2) in rat tibialis anterior muscle was markedly decreased following the injection of bradykinin. Injection of bradykinin also induced a significant increase in the level of cyclic GMP in muscle. The activity of glucose-1,6-bisphosphatase, the enzyme that degrades Glc-1,6-P2, was markedly enhanced by bradykinin, which may account for the decrease in the level of Glc-1,6-P2. The decrease in Glc-1,6-P2, the potent activator of phosphofructokinase and phosphoglucomutase, was accompanied by a concomitant reduction in these enzymes' activities. The bradykinin-induced decrease in Glc-1,6-P2 and in the activity of phosphofructokinase, the rate-limiting enzyme in glycolysis, may be involved in the pathogenic influences of this hormone in various clinical conditions.
D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage*; D006152:Cyclic GMP / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D019298:Glucose-6-Phosphate / Q000031:analogs & derivatives*; D005958:Glucosephosphates / Q000378:metabolism*; D007273:Injections, Intramuscular; D009132:Muscles / Q000378:metabolism*; D010732:Phosphofructokinase-1 / Q000378:metabolism*; D010733:Phosphoglucomutase / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism*; D051381:Rats
D005958:Glucosephosphates; D019298:Glucose-6-Phosphate; C016473:glucose-1,6-bisphosphate; D010732:Phosphofructokinase-1; C014818:glucose 1,6-diphosphate phosphatase; D010744:Phosphoric Monoester Hydrolases; D010733:Phosphoglucomutase; D006152:Cyclic GMP; D001920:Bradykinin